A new treatment for Type 2 diabetes has hit the headlines today. Liraglutide (Victoza), a oncedaily injectable treatment for Type 2 diabetes, is pharmaceutical company Novo Nordisks latest brain child.
From the Glucoagonlike peptide1 (GLP1) family of drugs, it can be taken any time of day, irrespective of meals. It helps to control Type 2 diabetes [...]

Research led by the German Institute of Human Nutrition (DIfE) has identified a new gene associated with diabetes, together with a mechanism that makes obese mice less susceptible to diabetes. A genomic fragment that occurs naturally in some mouse strains diminishes the activity of the risk gene Zfp69. The researchers also found that the corresponding [...]

InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides antidiabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.
The 4 week double blind placebo controlled [...]

The results of the LEAD6 study are published in an article Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association meeting in New Orleans, USA. They indicate that taking liraglutide once a day is more efficient in controlling blood glucose in [...]

MedImpact researchers and Health Alliance Medical Plans, a MedImpact client, presented findings from an important new study that evaluates the impact of valuebased benefit design (VBBD) on adherence to diabetes medications. Study results show that implementation of a VBBD program that reduced copayment by almost fifty percent for diabetic medications resulted in significantly improved medication [...]

Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the UK, which recommends considering a range of newer therapy options, including Januvia (sitagliptin). The guideline recommends that the DPP4 inhibitor class, which includes sitagliptin, [...]

A metaanalysis of five trials has shown that more intensive glucose control in type 2 diabetes leads to fewer heart attacks and heart disease events but has no significant effect on stroke or mortality from all causes. The findings are reported in an Article in this weeks diabetes special issue of The Lancet, written [...]

A drug being developed by DiaKine Therapeutics, Inc., which has shown in animals to prevent type 1 diabetes when given as a single therapy and to reverse diabetes when given in combination with a growth factor, is set to begin the first Companysponsored clinical trial in humans. It is also the first clinical trial where [...]